uniQure N.V.

NASDAQ:QURE

Biotechnology

Healthcare
$20.30 -2.34%

-$1.13 today

Market cap
$1.42B
Beta
1.00
P/E (TTM)
-14.1
EPS (TTM)
-$3.33
52W Low $8.73High $71.50

Volume 1.13M

Average 1.75M

QURE Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

uniQure N.V.NASDAQ: QURE

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 62.74M shares rose 18.1% year over year, ahead of the +17.2% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 9.1% from the prior quarter. Over 3 fiscal years it compounded at +7.2% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +18.1% holds above the trailing-twelve-month pace of +17.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
62.74M+9.1% QoQ
Last fiscal yearDec 2025
57.5M+18.2% YoY
LTMMar 2026
58.39M+17.2% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.1%——
1 year+18.2%——
3-year CAGR+7.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
57.5M USD
Year-over-year change
+18.2%
4-year CAGR
+5.3%

Weighted Avg Shares (Diluted) vs competitors

How QURE compares with its peers on the latest reported figures

  • QURE's LTM Mar 2026 weighted avg shares (diluted) of 58.39M shares is the 6th highest of the 8 companies compared; the peer median is 59.51M shares.
  • Its year-over-year change of +17.2% is the highest of 8, against a peer median of +7.9%.
  • Over three fiscal years its annual growth of +7.2% compares with a peer median of +17.7%.
QURE Competitors Peer median
Weighted Avg Shares (Diluted) for QURE and competitors
Company Period LTM YoY 3-year CAGR
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026111.46M +12.7%+17.7%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202699.68M +6.6%+12.1%
MGTXMeiraGTx Holdings plcLTM Mar 202680.99M +13.7%+21.2%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 202659.51M +7.9%+21.4%
VYGRVoyager Therapeutics, Inc.LTM Mar 202658.91M +1.6%+15.2%
QUREuniQure N.V.LTM Mar 202658.39M +17.2%+7.2%
RGNXREGENXBIO Inc.LTM Mar 202651.84M +1.8%+6.1%
NGNENeurogene Inc.LTM Mar 202620M +14.7%+18.2%
Peer median (excluding QURE) 59.51M+7.9%+17.7%

Competitors are the stored peer set for QURE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue524M106.48M15.84M27.12M16.1M
Cost of Revenue24.98M3.34M13.63M18.33M1.69M
Gross Profit499.03M103.14M2.22M8.79M14.41M
Gross Margin95.2%96.9%14.0%32.4%89.5%
Research & Development143.55M197.59M214.86M143.78M140.67M
Selling, General & Admin56.29M54.7M73.08M50.68M65.34M
Operating Expenses188.41M246.3M285.09M193.09M202.24M
Depreciation & Amortization7.3M8.54M11.9M12.64M14.76M
EBITDA319M(108.02M)(253.1M)(160.75M)(116.59M)
EBITDA Margin60.9%-101.4%-1597.6%-592.7%-724.2%
Operating Income310.62M(143.16M)(282.87M)(184.29M)(187.83M)
Operating Margin59.3%-134.4%-1785.5%-679.6%-1166.8%
Interest Income162K609K19.56M21.42M16.97M
Interest Expense7.47M11.7M41.56M63.74M61.99M
Other Income / Expenses22.19M14.9M(23.69M)(52.83M)(5.51M)
Income Before Tax332.81M(128.26M)(306.56M)(237.13M)(193.34M)
Pre-Tax Margin63.5%-120.5%-1935.0%-874.4%-1201.0%
Income Tax Expense3.22M(1.47M)1.92M2.43M5.63M
Net Income329.59M(126.79M)(308.48M)(239.56M)(198.97M)
Net Margin62.9%-119.1%-1947.1%-883.4%-1236.0%
EPS (Basic)7.17(2.71)(6.47)(4.92)(3.46)
EPS (Diluted)7.04(2.71)(6.47)(4.92)(3.46)
Weighted Avg Shares45.99M46.74M47.67M48.65M57.5M
Weighted Avg Shares (Diluted)46.84M46.74M47.67M48.65M57.5M

uniQure N.V.

NASDAQ:QURE

Intrinsic Alpha fair value

Locked

Current Price

$20.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.